Damon A Bell1, Jacquie Garton-Smith2, Alistair Vickery3, Andrew B Kirke4, Jing Pang5, Timothy R Bates6, Gerald F Watts6. 1. Lipid Disorders Clinic, Department of Internal Medicine, Royal Perth Hospital, Perth, Australia; Department of Clinical Biochemistry, Royal Perth Hospital, Perth, Australia; School of Medicine & Pharmacology, University of Western Australia, Perth, Australia. Electronic address: damon.bell@health.wa.gov.au. 2. Clinical Lead, Cardiovascular Health Network, DoHWA and Hospital Liaison GP, Royal Perth Hospital, Australia. 3. Primary Health Care - General Practice, SPARHC, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Perth, Australia. 4. Rural Clinical School of Western Australia, University of Western Australia, Perth, Australia. 5. School of Medicine & Pharmacology, University of Western Australia, Perth, Australia. 6. Lipid Disorders Clinic, Department of Internal Medicine, Royal Perth Hospital, Perth, Australia; School of Medicine & Pharmacology, University of Western Australia, Perth, Australia.
Abstract
AIM: To determine general practitioners' (GPs') knowledge and practice regarding familial hypercholesterolaemia (FH) in Western Australia. METHOD: A structured questionnaire was anonymously completed by GPs. Information was sought on awareness and knowledge of FH including, diagnosis, inheritance, prevalence, cardiovascular risk, management practices and opinions on FH screening. RESULTS: 191 GPs completed the survey, 62% were familiar with FH, 80% correctly defined FH and 68% identified the typical lipid profile, but only 33% were aware of national guidelines. There were knowledge deficits in prevalence, inheritance, and clinical features of FH, with correct responses in 27%, 45% and 38%, respectively. Most (84%) GPs considered themselves the most effective health professionals to detect FH, with 90% preferring laboratory interpretative commenting to highlight individuals at risk of FH. GPs identified appropriate cholesterol lowering drugs as mono (95%) or combination therapies (74%). CONCLUSION: The majority of GPs considered they were the most effective health practitioners for managing FH and preferred laboratory reports to alert them of possible FH. Although GPs knowledge of cholesterol lowering therapies was good, their awareness of national guidelines, hereditability, prevalence and diagnostic features of FH was suboptimal. Implementing a community model of care for FH requires more extensive GP education. Crown
AIM: To determine general practitioners' (GPs') knowledge and practice regarding familial hypercholesterolaemia (FH) in Western Australia. METHOD: A structured questionnaire was anonymously completed by GPs. Information was sought on awareness and knowledge of FH including, diagnosis, inheritance, prevalence, cardiovascular risk, management practices and opinions on FH screening. RESULTS: 191 GPs completed the survey, 62% were familiar with FH, 80% correctly defined FH and 68% identified the typical lipid profile, but only 33% were aware of national guidelines. There were knowledge deficits in prevalence, inheritance, and clinical features of FH, with correct responses in 27%, 45% and 38%, respectively. Most (84%) GPs considered themselves the most effective health professionals to detect FH, with 90% preferring laboratory interpretative commenting to highlight individuals at risk of FH. GPs identified appropriate cholesterol lowering drugs as mono (95%) or combination therapies (74%). CONCLUSION: The majority of GPs considered they were the most effective health practitioners for managing FH and preferred laboratory reports to alert them of possible FH. Although GPs knowledge of cholesterol lowering therapies was good, their awareness of national guidelines, hereditability, prevalence and diagnostic features of FH was suboptimal. Implementing a community model of care for FH requires more extensive GP education. Crown
Authors: Luisa Silva; Laura Condon; Nadeem Qureshi; Brittany Dutton; Stephen Weng; Joe Kai Journal: Br J Gen Pract Date: 2022-06-30 Impact factor: 6.302
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Mohammed Ali Batais; Turky H Almigbal; Aref A Bin Abdulhak; Hani B Altaradi; Khalid F AlHabib Journal: PLoS One Date: 2017-08-17 Impact factor: 3.240